RQ3013-VLP

An mRNA candidate COVID-19 vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

RQ3013-VLP is a lipid nanoparticle-delivered codon-optimized mRNA (encoding SARS-CoV-2 S, M, and E proteins) candidate vaccine (Lu et al., 2020).

Link	Tested on	Impact factor	Notes	Publication date
A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice Spike protein RNA Envelope protein Animal model	HEK 293A cells; BALB/c mice	15.92	The lipid nanoparticle-delivered codon-optimized mRNA (encoding SARS-CoV-2 S, M, and E proteins) vaccine induced production of virus-like particles which elicited humoral and T cell immune responses in mice. It also induced high neutralizing antibody titers against SARS-CoV-2.	Aug/17/2020